Condition: Advanced Malignant Solid Neoplasm · Metastatic Malignant Solid Neoplasm · Unresectable Malignant Solid Neoplasm · Sponsor: National Cancer Institute (NCI)
This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| National Cancer Institute Developmental Therapeutics Clinic | Bethesda, Maryland, United States | Recruiting |
| National Institutes of Health Clinical Center | Bethesda, Maryland, United States | Active Not Recruiting |
| Massachusetts General Hospital Cancer Center | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| NYU Langone Hospital - Long Island | Mineola, New York, United States | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05687136